Aker Horizons ASA (the "Company") hereby publishes its Annual Report 2024, which comprises the Board of Directors' Report including the Sustainability Statement, the consolidated accounts, parent ...
The Board of Directors proposes that the General Meeting approves the Board of Directors' proposal for the allocation of profit as stated in the Annual Report for 2024, including distribution of an ...
On 2 April 2024, the Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) decided: - To approve the ...
Nagpur: Spelling errors, incorrect titles, and photos without captions or missing information came to the fore during the ...
Copenhagen K Copenhagen, 26 March 2025 ANNOUNCEMENT no.10/2025 CEMAT A/SCompany reg. (CVR) no. 24 93 28 18Annual general meeting 2025 On 26 March 2025 at 1:00 pm the annual general meeting was held in ...
COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.Th ...
Aegon Ltd. today publishes its Integrated Annual Report 2024. The report also reflects on the key trends that influence Aegon's businesses and its stakeholders, and how these trends impact the way in ...
The mood is tense at CinemaCon this year, Variety's Brent Lang reports from Las Vegas on the latest episode of Variety ...
Syensqo releases 2024 annual integrated report Brussels, Belgium - March 28, 2025 - 08:30 CET Syensqo has published its 2024 annual integrated report today giving its stakeholders a comprehensive ...
A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website ... Investors should read the risk factors set forth in the Annual Report on Form 10-K for ...
U.S. added 228K jobs in March, beating forecasts despite a 4.2% unemployment rate. Click for my review of the employment data ...
About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...